Safety Risk Management Company Perspective
|
|
|
- Piers Holmes
- 8 years ago
- Views:
Transcription
1 Safety Risk Management Company Perspective Akihisa Harada, MD, Ph.D VP, Development Japan Pfizer Japan Inc. R&D Head Club
2 Agenda REMS in FDAAA Safety Risk Management throughout a Drug s Lifecycle Risk Communications Conclusions cuso s
3 What is Risk Management Comprehensive and proactive science based methodologies Identify safety risk earlier Assess appropriately Communication Minimize i i risk Establish benefit risk profile
4 Risk Evaluation and Mitigation Strategies (REMS) in US PDUFA IV FDA Safety Five-year plan (draft Mar. 2008,) Required Based on FDA Benefit-Risk Assessment with $250 K - $10 MM REMS violation penalties REMS Elements: Medication Guide Risk Communication Plan Elements to Assure Safe Use Implementation System Assessment of REMAS: Timetable of Assessments Information needed for Assessment
5 Safety Risk Management throughout a Drug s Lifecycle
6 Risk management across the product lifecycle Product Life Cycle Animal studies Drug Discovery/Preclinical FIM Ph I Ph II Ph III Ph IV Clinical Development Approval Post Approval Pharmacovigilance Estimate potential benefit Understand the disease Predict potential candidates Disease Mechanism of Action Studies Studies to better understand population, risks, etc ID potential signals Promote better approval analysis Achieve appropriate label Address any new emerging safety issues Post-approval studies and epidemiology Signal detection Product defense risk management planning
7 Understanding Risk and Accumulation of Knowledge of Safety Profile Earlier Risk Management Planning is key for successful product life cycle management Clinical Studies Background Spontaneous Observational Other Epidemiology Reports Studies Activities POTENTIAL RISK IDENTIFIED FROM NON-CLINICAL STUDIES INCIDENCE OF COMMONLY OCCURRING EVENT FROM CLINICAL TRIALS INCIDENCE OF EVENT IN GENERAL POPULATION IDENTIFICATION OF RISK FACTORS 1/10,000 POTENTIAL SIGNALS OF RARE EVENTS 1/100,000 HYPOTHESIS TESTING 1/1,000,000 1/500, /1,000 1/500 1/100 1/5,000 1/1,000 1/50,000 1/10,000 1/100,000, Risk Management/Assessment Strategy
8 Risk Management Committee (RMC) Sub-team of Development Team: formed at Phase IIB Clinical i l & nonclinical i l safety stakeholders Risk Log: documents both observed and hypothetical risks Plans for signal detection, assessment, and mitigation Forum for discussion of safety issues throughout a product life cycle A forum to formalize the Safety Risk Management program for a compound
9 RMC Activities Step 1: Identify and Assess a product s benefit-risk balance Step 4: Modify risk minimization tools to further improve benefit-risk balance RMC Step 3: Evaluate tool effectiveness and reassess the benefit-risk balance Step 2: Develop and implement tools minimize risks - preserve benefits Communication of Risk Internally and Externally
10 Implementation of RMP in Japan Safety Specifications Global-RMP Pharmacovigilance Plan Japan Appendix (J-RMP) Basic Plan for Post Marketing Surveillance Basic Plan for Post Marketing Surveillance Common Technical Document J-CTD module 1
11 How effectively implement RMP in Japan? Basic PMS Plan at J-NDA effective enough? Should we wait the discussion until later stage of J-NDA review? Initiation of discussions i on RMP should be more earlier development stage Should we have new category of PMDA consultation, Risk Management Plan consultation?
12 Risk Communications
13 External Risk Communication Regulators Physicians/Investigators/Patients Telecons & F2F meetings Pre-Clinical Study Reports Clinical Study Reports License Applications Regulatory Briefing Documents Regulatory Reports Risk Management Plans Safety Investigator Reports Investigator Brochures Informed Consent Ethics Committees Web Site/ DTC (US) Dear HCP Letters Publications Reports to External Data Safety Monitoring Boards Expert Panels/ Scientific Advisory Boards Product Labels
14 Chantix: Medication Guide (US) What do you need to know? The most important information that patients should know Immediate action that patient should take if that happens Next action that t patient t should take after immediate action Common side effect Other precautions
15 Medicine Safety Web Site -Direct communication to patients and healthcare providers- In Industry First, the Web site is launched to improve understanding of how risks and benefits of medicine are determined, d monitored and communicated. A clear need to increase awareness of medicine safety among patients, healthcare providers and professionals This site delineates the role of Pharmaceutical companies The regulatory office Healthcare provider
16 Sutent: Company Web information (Japan)
17 Risk Communication Health Care Professionals Patient Regulator Company Patient s Safety First
18 Conclusions Increased focus on Safety and Risk Management is a global issue with diminishing boundaries Focus is representative of the entire lifecycle of a drug as knowledge and experience further develops and expands with drug use. Development of Global Risk Management Plan rather than individual region or country Risk Management Plans would be an important t step forward to more effectively and accurately assess the safety of pharmaceutical drug products. Earlier Risk Management Planning b/w Company, Regulator and Healthcare Professionals is key for successful u product life cycle management age e Risk Communication Plan b/w Company, Regulator, Healthcare Professionals and Patients is getting more important
19
Risk Management Plan (RMP) on Biologicals and NCE
Transformation towards a New Regulatory Paradigm Risk Management Plan (RMP) on Biologicals and NCE Junko SATO International Coordination Officer PMDA, Japan 1 2 Pharmaceuticals and Medical Devices Agency
Risk Management Plan (RMP) Guidance (Draft)
Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour
Medicine Safety Glossary
The following definitions are provided as a resource to supplement the information provided in the Medicine Safety Education section of the Pfizer.com Web site; they are not intended as a comprehensive
Update From the Office of Surveillance and Epidemiology
Update From the Office of Surveillance and Epidemiology Gerald J. Dal Pan, MD, MHS Director Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Presentation to FDA-CMS Summit
Risk Assessment in the Pharmaceutical Industry. Dorothea Köppe Liability Insurance: The Never-ending Story September 9th, 2009
Dorothea Köppe Liability Insurance: The Never-ending Story September 9th, 2009 - the 6 W WER WAS WANN WO WIE WARUM WHO WHAT WHEN WHERE HOW WHY 2009 Page 2 _10-Sep-09 Definitions 2009 Page 3 _10-Sep-09
Risk Management in the Pharmaceutical Industry. Elena Apetri, Global Medical Safety Surveillance Schering AG
Risk Management in the Pharmaceutical Industry Elena Apetri, Global Medical Safety Surveillance Schering AG Topics Environment Safety Risk Management Guidance Safety RM Systems Signal detection and evaluation
Stakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes
Stakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes Dr Anya Sookoo, Expert Inspector, Inspections, Enforcement & Standards Division,
Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER
Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER LT Andrew Fine, Pharm.D., BCPS Safety Evaluator Division of Pharmacovigilance Office of Pharmacovigilance and Epidemiology
TYSABRI Risk Management Plan. Carmen Bozic, MD Vice President Drug Safety and Risk Management Biogen Idec Inc
76 TYSABRI Risk Management Plan Carmen Bozic, MD Vice President Drug Safety and Risk Management Biogen Idec Inc 77 Presentation Outline Overview and Goals of Plan Risk Minimization Plan Risk Assessment
Safety Is Global: Contemporary Pharmacovigilance and Medical Product Risk Management Strategies
Safety Is Global: Contemporary Pharmacovigilance and Medical Product Risk Management Strategies CLICK HERE to register. PROGRAM COMMITTEE WHO SHOULD ATTEND This program will benefit professionals with
The Product Review Life Cycle A Brief Overview
Stat & Quant Mthds Pharm Reg (Spring 2, 2014) Lecture 2,Week 1 1 The review process developed over a 40 year period and has been influenced by 5 Prescription User Fee Act renewals Time frames for review
298.015) UC 6:30 8:20 PM
Course Description: This course is an in depth review of the history, authorizing statute and regulatory authority of US FDA and the influence and impact of FDA on science and health policy. Drug development,
Guidance Medication Guides Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)
Guidance s Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
US Perspective on the Regulatory Assessment of Benefit-Risk of Vaccines
US Perspective on the Regulatory Assessment of Benefit-Risk of Vaccines Norman W. Baylor Biologics Consulting Group, Inc. 23-25 June 2014 Foundation Merieux Conference Center OUTLINE OF PRESENTATION Introduction
EMEA RM DRAFT GUIDANCE ISPE RESPONSE 1
EMEA RM DRAFT GUIDANCE ISPE RESPONSE 1 October 4, 2005 Guideline on Risk Management Systems for Medicinal Products for Human Use DRAFT London, 6 September 2005. This guideline will be included as chapter
Overview of FDA s active surveillance programs and epidemiologic studies for vaccines
Overview of FDA s active surveillance programs and epidemiologic studies for vaccines David Martin, M.D., M.P.H. Director, Division of Epidemiology Center for Biologics Evaluation and Research Application
Risk Management Plan for Drug Establishments
Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION Risk Management Plan for Drug Establishments Center for Drug Regulation and Research Food and Drug Administration 17 December
Overview of Risk Management
Overview of Risk Management Risk Management Plans- An Industry Perspective Dr. Sudhichai Chokekijchai, CSO Novartis (Thailand) Limited (adapted from an RMP training by Dr Judith Sills, Global Head, Medical
GUIDELINE ON THE SUBMISSION OF RISK MANAGEMENT PLAN DOCUMENTS
APPENDIX GUIDELINE ON THE SUBMISSION OF RISK MANAGEMENT PLAN DOCUMENTS This document is intended to provide guidance on the submission of risk management plan (RMP) documents in support of NDA, GDA and
RAPS ONLINE UNIVERSITY
RAPS ONLINE UNIVERSITY Practical education and training for business success. For regulatory professionals, there is only one name to know and trust for online education and training RAPS Online University.
DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications DRAFT GUIDANCE This guidance document is being distributed
FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE
FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE Marion Gruber, Ph.D. Director Office of Vaccines Research & Review Center for Biologics Evaluation and Research US Food and Drug Administration
Quality by Design Concept
3rd Jerusalem Conference on Quality and Pharma Sciences 6-7 June, 2012 QbD in Clinical Research - Where Can QbD Impact Clinical Research Practices? Dr. Yafit Stark Vice President, TEVA Pharmaceutical Industries,
COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/044/99-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT
Why Are Drugs So Expensive? Learning About the Drug Development Process
Why Are Drugs So Expensive? Page 1 of 92 Why Are Drugs So Expensive? Learning About the Drug Development Process written by: Ann Newman Seventh Street Development Group This product is for your Personal
Risk Management Plan - Bayer Experience :
Risk Management Plan - Bayer Experience : Organization & Processes Najoua ADYEL Pharmacovigilance Country Head Maghreb Introduction: Pharmacovigilance toward maturity 50 s and 60 s: from nothing to reacting
Clinical trials in haemophilia
Clinical trials in haemophilia Dr. Paul Giangrande Oxford Haemophilia and Thrombosis Centre & Nuffield Department of Clinical Medicine University of Oxford paul.giangrande@ndm.ox.ac.uk Why do clinical
Risk management plans an overview
Risk management plans an overview Elspeth Kay Director, Risk Management Plan Evaluation Section, Post-marketing Surveillance Branch, Monitoring and Compliance Division, TGA ARCS-TGA workshop 12 March 2015
Prescription Drug Information for Patients: History
Prescription Drug Information for Patients: History 1500s: Ethical Statutes of Royal College of Physicians Let no physician teach the people about medicines or even tell them the names of the medicines,
PHARMACOVIGILANCE IN A BOX
PHARMACOVIGILANCE IN A BOX Evolution of Pharmacovigilance Over the years the role of Pharmacovigilance or Product Vigilance (PV) has changed from capturing and reporting adverse events to a business imperative
Careers in Medical and Scientific Writing
Careers in Medical and Scientific Writing Laura McCormick, PhD Vice President Associate Practice Leader Tamara Fink, PhD Associate Scientific Director ProEd Communications, Inc Beachwood, Ohio Agenda Introduction
Detailed guidance AEs reporting in clinical trials ( CT-3 ) Stefano Bonato, M.D. Pharmacovigilance Country Head Bayer HealthCare Pharmaceuticals
Detailed guidance AEs reporting in clinical trials ( CT-3 ) Stefano Bonato, M.D. Pharmacovigilance Country Head Bayer HealthCare Pharmaceuticals Pharmacovigilance costs 0.12%-0.22% of hospital admissions
Background: Pathways for the Master s Degree (Thesis and Non Thesis)
Differences between the Non Thesis (Project) and Thesis Options for the M.S. in Pharmacy with an emphasis in BioPharma Regulatory Affairs Offered by the University of Georgia College of Pharmacy Background:
Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009
Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009 The innovative pharmaceutical industry 2 is committed to the transparency
Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset
Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Introduction In this era of strategic development deals, inventiv Health has significantly broadened
REMS: The New Reality
Kuyler Doyle, Principal Consultant, Campbell Alliance Jay Jauregui, Senior Practice Executive, Trade and Distribution Practice Gary Tyson, Senior Vice President, Clinical Development and Medical Affairs
Comparison of Clinical Trials Registry Legislation in the Senate and House Prepared by Tannaz Rasouli, AAMC Office of Governmental Relations
Comparison of Clinical Trials Registry Legislation in the Senate and House Prepared by Tannaz Rasouli, AAMC Office of Governmental Relations Clinical Trials Registry S. 1082 (Title II, Subtitle C) H.R.
EMA Update Clinical Trials
EMA Update Clinical Trials Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency 16 October 2012 An agency of the European Union Disclaimer The views presented in this presentation/these
Enabling Patient Safety Through Risk Management: The Role of Epidemiology
Enabling Patient Safety Through Risk Management: The Role of Epidemiology Robert Reynolds, ScD Vice President, Epidemiology Safety & Regulatory 2014 ICPE Pre-Conference Educational Session: Topics in Pharmacoepidemiology
Risk Assessment and Management: A Regulatory Lawyer s Perspective
Risk Assessment and Management: A Regulatory Lawyer s Perspective Presented By: Alan G. Minsk Partner and Leader, Food and Drug Practice Team Arnall Golden Gregory LLP 171 17 th Street, NW, Suite 2100
How To Understand The Pharmacology Of The Pharmaceutical Industry
It; MM MODERN Ul NDUSTRY 77 /
Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program
Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program DRAFT GUIDANCE This guidance document is being distributed for comment purposes
Guidance for Industry
Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
Application Submitted on Received on Supplement type NDA 021875/S-005 July 24, 2008 July 25, 2008 Changes Being Effected
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 021875/S-005, S-008, S-015 SUPPLEMENT APPROVAL Cephalon Inc. Attention: Paul Kirsch Senior Director and Group
Agenda. Med Tox and the MPH. Medical Toxicology and the Masters in Public Health Degree 3/24/14
Medical Toxicology and the Masters in Public Health Degree Stephen Munday, MD MS MPH FACMT Medical Toxicologist, Sharp Rees-Stealy Medical Group, Inc. San Diego California Poison Control Center *Joshua
Risk Management Process. Plan for the Workshop. Risk/Benefit Assessment Working Group. Topics of Interest. Objectives
Risk Management Process BALANCING RISKS AND BENEFITS OF HEALTH CARE TREATMENTS IN THE 21 ST CENTURY Communication (Creating balanced perceptions of risk/benefit) Assessment of Potential Risk Intervention
How Public-Private Partnerships Benefit All Stakeholders Douglas C. Throckmorton, MD Deputy Director for Regulatory Programs, CDER, FDA
How Public-Private Partnerships Benefit All Stakeholders Douglas C. Throckmorton, MD Deputy Director for Regulatory Programs, CDER, FDA September 10, 2013 Outline Need for improved science in support of
GUIDELINES ON MEDICAL DEVICES
EUROPEAN COMMISSION DIRECTORATE GENERAL for HEALTH and CONSUMERS Consumer Affairs Health technology and Cosmetics MEDDEV 2.12/2 rev2 January 2012 GUIDELINES ON MEDICAL DEVICES POST MARKET CLINICAL FOLLOW-UP
What Lies Ahead? Trends to Watch: Health Care Product Development in North America
What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the
U.S. Food and Drug Administration Center for Devices and Radiological Health REGULATORY SCIENCE PRIORITIES (FY2016)
U.S. Food and Drug Administration Center for Devices and Radiological Health REGULATORY SCIENCE PRIORITIES (FY2016) Executive Summary October 20, 2015 The Regulatory Science Subcommittee (RSS) of the CDRH
OECD Recommendation on the Governance of Clinical Trials
OECD Recommendation on the Governance of Clinical Trials Marketing authorisation status of the medicinal products Non-authorised medicine Authorised medicine, treatment regimen outside
Clinical Trials and Safety Surveillance of Drugs in Development
Clinical Trials and Safety Surveillance of Drugs in Development Hoda Eid, M.Sc., Ph.D. Manager, ADR Unit Office of Clinical Trials Therapeutic Products Directorate hoda_eid@hc-sc.gc.ca Overview Clinical
First In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases
First In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases Andrew E. Mulberg, MD, FAAP Division Deputy Director OND/ODE3/DGIEP FDA Partnership is the Key Coming together is a beginning;
PRODUCT RESEARCH & DEVELOPMENT PROCESS
0 :: 2 v01 x y p.345 B xxx.:: B A x y pval«««[xy] -løøøø xxx.:: øøøø -0.02-0.01-0.00 0.00 0.01 0.02.1.2 A PHARMATRAIN CENTRE OF EXCELLENCE INTRODUCTORY MODULE: PRODUCT RESEARCH & DEVELOPMENT PROCESS Aveiro
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034. Phone: 267.468.8560 Fax: 267.468.
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Phone: 267.468.8560 Fax: 267.468.8565 POST-MASTER S CERTIFICATE in GLOBAL PHARMACOVIGILANCE: BENEFIT-RISK ASSESSMENT Temple created
NDA 202439/S-008 SUPPLEMENT APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 202439/S-008 SUPPLEMENT APPROVAL Janssen Pharmaceuticals, Inc. ATTENTION: Alla Rhoge Pharm.D., Associate
The Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
Medical Toxicology and the Masters in Public Health Degree
Medical Toxicology and the Masters in Public Health Degree Stephen Munday, MD MS MPH FACMT Medical Toxicologist, Sharp Rees-Stealy Medical Group, Inc. San Diego California Poison Control Center *Joshua
Introduction to Post-marketing Drug Safety Surveillance Pharmacovigilance Practice:
Introduction to Post-marketing Drug Safety Surveillance Pharmacovigilance Practice: US Perspective Min Chen, M.S. R.Ph. Pharmacovigilance Consulting, LLC The opinions expressed are those of the author.
Introduction to Compliance with FDA Labeling and Advertising Requirements
Introduction to Compliance with FDA Labeling and Advertising Requirements Second Annual Pharmaceutical Industry Regulatory and Compliance Summit Dick Kenny FDA History Basic function of government Oldest
Clinical Communications Programs with Healthcare Professionals and Patients
A Multichannel Approach Clinical Communications Programs with Healthcare Professionals and Patients A Publicis Touchpoint Solutions White Paper Best Practices Series 2011 Publicis Touchpoint Solutions,
RISK MANAGEMENT PLANNING AND MANDATED POST-AUTHORIZATION STUDIES
RISK MANAGEMENT PLANNING AND MANDATED POST-AUTHORIZATION STUDIES Risk Management & Late Phase Studies in Real-World Research HARALD LANDEN, DR med, DR rer nat Executive Director, Safety & Risk Management,
FDA Tobacco Regulatory Science Fellowship
FDA Tobacco Regulatory Science Fellowship Program Overview FDA Tobacco Regulatory Science Fellowship Launched in 2012, this regulatory science fellowship is a collaborative program between the FDA Center
Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle
Quality Risk Management 11 November 2011 Galway, Ireland Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Overview Regulatory
Goals & Objectives. Drug Development & the FDA Pharmacy 309. Outline. An History of Disasters. Be able to describe
Drug Development & the FDA Pharmacy 309 Tom Hazlet, Pharm.D., Dr.P.H. 616-2732 thazlet@u... Goals & Objectives Be able to describe the major regulatory events in the drug development process the concepts
ICH guideline E2C (R2) Periodic benefit-risk evaluation report (PBRER)
April 2012 EMA/CHMP/ICH/544553/1998 Committee for medicinal products for human use (CHMP) ICH guideline E2C (R2) Periodic benefit-risk evaluation report (PBRER) Step 3 Transmission to CHMP 16 April 2012
Pharmaceutical Quality & Clinical Research Quality: The Interaction
4 th Jerusalem Conference: Quality by Design (QbD)) & Pharma Sciences, May 20-22, 2014 The Edmund Safra Campus, The Hebrew University of Jerusalem Pharmaceutical Quality & Clinical Research Quality: The
Safety Monitoring in Clinical Trials
Pharmaceutics 2013, 5, 94-106; doi:10.3390/pharmaceutics5010094 OPEN ACCESS pharmaceutics ISSN 1999-4923 www.mdpi.com/journal/pharmaceutics Article Safety Monitoring in Clinical Trials Bin Yao *, Li Zhu,
Certified National Pharmaceutical Representative
Certified National Pharmaceutical Representative 120 hours Course Overview/Description The Certified National Pharmaceutical Representative (CNPR) online training program was developed in partnership with
MedDRA in clinical trials industry perspective
MedDRA in clinical trials industry SFDA ICH MedDRA Workshop, Beijing, 13 14 May 2011 Christina Winter, MD, FFPM Medical director GlaxoSmithKline R&D / ICH MedDRA Management Board 2011 ICH International
A Health Outcomes Approach to the Pre-Marketing Quantitative Risk-Benefit Modeling of New Pharmaceuticals
A Health Outcomes Approach to the Pre-Marketing Quantitative Risk-Benefit Modeling of New Pharmaceuticals Presentation to Institute of Medicine Forum on Drug Discovery, Development, and Translation: Understanding
Data Standards in Clinical Trials, A Regulatory Perspec9ve
Data Standards in Clinical Trials, A Regulatory Perspec9ve NIH Data Standards Forum: Maximizing Innova8on by Standardizing Mary Ann Slack Center for Drug Evalua9on and Research (CDER) U.S. Food and Drug
Challenges in the Regulation of Pediatric Clinical Trials
Challenges in the Regulation of Pediatric Clinical Trials Wilson W. Bryan, M.D. FDA / CBER / OCTGT wilson.bryan@fda.hhs.gov National Institutes of Health Recombinant DNA Advisory Committee (RAC) Meeting
R&D Compliance: Prepare Now for Future Enforcement
R&D Compliance: Prepare Now for Future Enforcement Dennis K. Barnes, JD, MBA, CPA VP, Chief Compliance Officer Parexel International Paul Curtin, JD, CFE Exec. Director, R&D Compliance Allergan George
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034. Phone: 267.468.8560 Fax: 267.468.
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034 Phone: 267.468.8560 Fax: 267.468.8565 POST-MASTER S CERTIFICATE in CLINICAL TRIAL MANAGMENT Designed for Pharmaceutical
Lessons for the United States: Biosimilar Market Development Worldwide
Lessons for the United States: Biosimilar Market Development Worldwide Sumant Ramachandra, MD, PhD, MBA Senior Vice President, Chief Scientific Officer Hospira $67B+ of 2012 LMV is expected to face biosimilar
Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130
Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 12 Summary of Product Characteristics
DEPARTMENT OF HEALTH & HUMAN SERVICES NDA 17-854 NDA 21-793 NDA 17-862. [inside address] Dear :
![DEPARTMENT OF HEALTH & HUMAN SERVICES NDA 17-854 NDA 21-793 NDA 17-862. [inside address] Dear :](/thumbs/24/3528188.jpg "DEPARTMENT OF HEALTH & HUMAN SERVICES NDA 17-854 NDA 21-793 NDA 17-862. [inside address] Dear :")
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 NDA 17-854 [inside address] Dear : Please refer to your new drug application NDA xx-xxx for
February 2006 Procedural
Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and
School of Pharmacy TEMPLE UNIVERSITY
School of Pharmacy TEMPLE UNIVERSITY Regulatory Affairs and Quality Assurance Graduate Program Te mple Unive rsity School of Pharmacy Re gulatory Affairs and Quality Assurance Graduate Program 4 25 Comme
Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291
Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Steps Taken for Assessment Page 13 Summary of Product Characteristics
The AVAREF joint review process of Ebola clinical trial applications
The AVAREF joint review process of Ebola clinical trial applications Dr Matthias Stahl, Regulation, Ebola R&D Team 1 Background WHO convened the 9 th annual meeting of the African Vaccine Regulatory Forum
Overview of Drug Development: the Regulatory Process
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
School of Pharmacy TEMPLE UNIVERSITY
School of Pharmacy TEMPLE UNIVERSITY Regulatory Affairs and Quality Assurance Graduate Program Te mple Unive rsity School of Pharmacy Re gulatory Affairs and Quality Assurance Graduate Program 4 25 Comme
Robust Vendor Relationships, Agreements, and Training: Why, When, Where, and How
Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Robust Vendor Relationships, Agreements, and Training: Why, When, Where, and How Mark DeWyngaert, PhD MBA Managing Director, Huron
A Primer: Solving the Unique Problems of Orphan Drug Communications Programs
A Primer: Solving the Unique Problems of Orphan Drug Communications Programs Introduction When communicating about orphan diseases and development of pharmaceuticals, it is essential to recognize the special
Post-Doctoral Pharmaceutical Industry Fellowships. Two-Year Clinical Development Program Two-Year Clinical Safety Program
Post-Doctoral Pharmaceutical Industry Fellowships Two-Year Clinical Development Program Two-Year Clinical Safety Program Today, we innovate by creating new medicines, as well as new methods of drug discovery
2 December 2010. Dear Professor Pearce. Re: TGA Transparency Review
2 December 2010 Dear Professor Pearce Re: TGA Transparency Review I congratulate you on your appointment as Chair of the stakeholder panel for the Review of Transparency of the Therapeutic Goods Administration
SUMMARY OF COMPREHENSIVE COMPLIANCE PROGRAM
1. Introduction SUMMARY OF COMPREHENSIVE COMPLIANCE PROGRAM The Medicines Company (the Company ) is committed to establishing and maintaining an effective compliance program that promotes ethical conduct
A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations
A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations Ce3, Inc. and Insight Genetics, Inc. Oncology Forum July 15, 2015 Agenda Introductions Definitions Regulations
Big Data for Patients (BD4P) Program Overview
Big Data for Patients (BD4P) Program Overview [Updated August 5, 2015] Proposal: Big Data for Patients (BD4P) Training Program Page 1 Background The new and emerging field of data science ( Big Data )
Quality Considerations for Breakthrough Therapies-FDA Perspective
Quality Considerations for Breakthrough Therapies-FDA Perspective DIA June 17, 2014 Ramesh K. Sood, Ph.D. Acting Division Director and Angelica Dorantes, Ph.D. xxx ONDQA/OPS/CDER/FDA 1 Background Outline
Nutraceutical Medical Research, LLC. By: Latesha Richards, Marketing Coordinator
The Value of Conducting Post-Marketing Clinical Research On Marketing Strategy Development Nutraceutical Medical Research, LLC By: Latesha Richards, Marketing Coordinator Those of us who are marketing
Questions & answers on signal management
23 October 2015 EMA/261758/2013 Inspections and Human Medicines Pharmacovigilance Division This document addresses a number of questions which stakeholders, in particular marketing authorisation holders
FDA LACKS COMPREHENSIVE DATA TO DETERMINE WHETHER RISK EVALUATION AND MITIGATION STRATEGIES IMPROVE DRUG SAFETY
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL FDA LACKS COMPREHENSIVE DATA TO DETERMINE WHETHER RISK EVALUATION AND MITIGATION STRATEGIES IMPROVE DRUG SAFETY Daniel R. Levinson Inspector
MEDICAL DEVICE & DIAGNOSTICS
to Guide Strategic Medical Device and Introduction Medical device and diagnostic makers face myriad challenges when developing a new product, including working within resource and financial constraints,
Vertex Investigator-Initiated Studies Program Overview
Vertex Investigator-Initiated Studies Program Overview Our Goal To support independent, investigator-initiated research designed to advance scientific knowledge of disease states, patient populations,
THE BIOTECH & PHARMACEUTICAL INDUSTRY
THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues
Concepts in Pharmaceutical Development Project Management. Christopher D. Breder, MD PhD. Clinical Team Leader, Anesthetic Drugs
Concepts in Pharmaceutical Development Project Management Christopher D. Breder, MD PhD Clinical Team Leader, Anesthetic Drugs Division of Anesthesia, Analgesia, and Addiction Products Disclaimer The views